Skip to main content

Table 4 Univariate and multivariate analyses for PFS and OS based on TTC

From: Timing of interval debulking surgery and postoperative chemotherapy after neoadjuvant chemotherapy in advanced epithelial ovarian cancer: a multicenter real-world study

 

PFS

OS

 

Univariate analysis

Multivariate analysis

Univariate analysis

Multivariate analysis

 

HR (95%CI)

P value

HR (95%CI)

P value

HR (95%CI)

P value

HR (95%CI)

P value

Age, years

< 54

1 (Reference)

 

1 (Reference)

 

1 (Reference)

 

1 (Reference)

 

≥ 54

1.02 (0.85–1.23)

0.827

0.94 (0.78–1.13)

0.509

1.18 (0.93–1.49)

0.175

1.04 (0.82–1.32)

0.749

Type

Serous

1 (Reference)

 

1 (Reference)

 

1 (Reference)

 

1 (Reference)

 

Other

1.24 (0.96–1.60)

0.098

1.15 (0.87–1.52)

0.326

1.15 (0.84–1.59)

0.385

1.09 (0.77–1.55)

0.613

Grade

Other

1 (Reference)

 

1 (Reference)

 

1 (Reference)

 

1 (Reference)

 

High

1.25 (0.98–1.60)

0.077

1.12 (0.85–1.47)

0.418

1.06 (0.78–1.44)

0.709

1.00 (0.72–1.39)

0.985

FIGO Stage

IIIC

1 (Reference)

 

1 (Reference)

 

1 (Reference)

 

1 (Reference)

 

IV

0.97 (0.80–1.17)

0.741

0.88 (0.71–1.07)

0.200

1.01 (0.79–1.30)

0.935

0.91 (0.71–1.18)

0.484

Upper abdominal surgery

No

1 (Reference)

 

1 (Reference)

 

1 (Reference)

 

1 (Reference)

 

Yes

1.29 (0.97–1.72)

0.083

1.27 (0.94–1.71)

0.113

0.82 (0.54–1.26)

0.377

0.80 (0.52–1.25)

0.328

Bowel resection

No

1 (Reference)

 

1 (Reference)

 

1 (Reference)

 

1 (Reference)

 

Yes

1.18 (0.91–1.54)

0.209

1.09 (0.83–1.43)

0.556

1.46 (1.06-2.00)

0.02

1.36 (0.98–1.87)

0.064

Lymphadenectomy

No

1 (Reference)

 

1 (Reference)

 

1 (Reference)

 

1 (Reference)

 

Yes

0.73 (0.60–0.87)

0.001

0.73 (0.60–0.88)

0.001

0.72 (0.57–0.91)

0.006

0.76 (0.59–0.97)

0.030

Residual disease

R0

1 (Reference)

 

1 (Reference)

 

1 (Reference)

 

1 (Reference)

 

R1

1.52 (1.24–1.87)

< 0.001

1.56 (1.26–1.92)

< 0.001

1.52 (1.16–1.99)

0.002

1.51 (1.14–1.99)

0.004

R2

1.61 (1.25–2.08)

< 0.001

1.55 (1.19–2.02)

0.001

1.89 (1.37–2.59)

< 0.001

1.89 (1.35–2.64)

< 0.001

Postoperative complication

No

1 (Reference)

 

1 (Reference)

 

1 (Reference)

 

1 (Reference)

 

Yes

1.26 (1.05–1.51)

0.014

1.17 (0.97–1.42)

0.100

1.44 (1.14–1.82)

0.003

1.28 (1.00-1.63)

0.050

NACT cycle

≤ 3

1 (Reference)

 

1 (Reference)

 

1 (Reference)

 

1 (Reference)

 

> 3

1.08 (0.86–1.36)

0.509

1.21 (0.95–1.53)

0.119

1.06 (0.79–1.42)

0.714

1.15 (0.85–1.56)

0.372

TTC

≤ 40

1 (Reference)

 

1 (Reference)

 

1 (Reference)

 

1 (Reference)

 

> 40

1.09 (0.90–1.3)

0.376

1.07 (0.89–1.30)

0.469

1.34 (1.06–1.69)

0.016

1.34 (1.05–1.71)

0.018

  1. Abbreviation: PFS, Progression-free survival; OS, Overall survival; FIGO, International Federation of Gynecology and Obstetrics; NACT, Neoadjuvant chemotherapy; TTC, Time to postoperative adjuvant chemotherapy after the completion of neoadjuvant chemotherapy; HR, Hazard ratio; CI, Confidence interval